Should the government regulate the prices of life-saving drugs?

In September of 2016, US Presidential candidate Hillary Clinton released a proposal that would create an oversight panel that would protect U.S. consumers from large price hikes on long-available, lifesaving drugs. The proposal was in response to recent steep price increases on drugs including the AIDS drug Daraprim and the EpiPen. Proponents of drug price regulation argue that drug makers raise prices to benefit the value of their stock and invest little of their profits in the development and research of new drugs. Opponents of regulation argue that consumers rely on drug companies to develop new drugs and limiting prices will prevent new lifesaving drugs from being developed. Clinton's campaign cited Turing Pharmaceuticals LLC's raising the price of its AIDS drug Daraprim (pyrimethamine) and Mylan NV’s repeated steep price increases on EpiPen for severe allergy sufferers as “troubling” examples of price hikes that have attracted bipartisan congressional scrutiny.

Learn more Stats Discuss